Skip to main content
. Author manuscript; available in PMC: 2018 Jun 8.
Published in final edited form as: iScience. 2018 Apr 27;2:221–237. doi: 10.1016/j.isci.2018.03.005

Table 1.

Top Canonical Pathways Regulated by CL316,243 in WT BAT and Their Ranking in ERRαγAd−/− BAT

Canonical Pathway WT Mice ERRαγAd−/− Mice
Rank Downregulated Upregulated −log(p Value) Rank Downregulated Upregulated −log(p Value)
Mitochondrial dysfunction 1 8/142 (6%) 79/142 (56%) 9.29E+00 NA
Oxidative phosphorylation 2 2/85 (2%) 62/85 (73%) 8.92E+00 NA
TCA cycle II (eukaryotic) 3 0/19 (0%) 17/19 (89%) 7.22E+00 27 0/19 (0%) 13/19 (68%) 2.03E+00
Fatty acid β-oxidation I 4 0/26 (0%) 16/26 (62%) 6.80E+00 1 0/26 (0%) 21/26 (81%) 8.28E+00
Glutaryl-CoA degradation 5 1/15 (7%) 11/15 (73%) 6.66E+00 39 1/15 (7%) 11/15 (73%) 1.72E+00
Tryptophan degradation III (eukaryotic) 6 1/15 (7%) 11/15 (73%) 6.66E+00 40 1/15 (7%) 11/15 (73%) 1.72E+00
Valine degradation I 7 0/17 (0%) 13/17 (76%) 5.81E+00 8 0/17 (0%) 15/17 (88%) 4.01E+00
Acetyl-CoA biosynthesis I (pyruvate dehydrogenase complex) 8 0/5 (0%) 5/5 (100%) 4.34E+00 215 0/5 (0%) 3/5 (60%) 5.08E−01
Allograft rejection signaling 9 11/19 (58%) 0/19 (0%) 4.23E+00 5 12/19 (63%) 0/19 (0%) 4.60E+00
LXR/RXR activation 10 13/64 (20%) 16/64 (25%) 4.20E+00 15 17/64 (27%) 8/64 (13%) 2.76E+00
Autoimmune thyroid disease signaling 11 9/13 (69%) 0/13 (0%) 4.12E+00 30 8/13 (62%) 1/13 (8%) 1.95E+00
Isoleucine degradation I 12 1/13 (8%) 9/13 (69%) 4.12E+00 69 1/13 (8%) 11/13 (85%) 1.21E+00
Complement system 13 13/23 (57%) 1/23 (4%) 4.11E+00 3 14/23 (61%) 2/23 (9%) 6.83E+00
Antigen presentation pathway 14 11/24 (46%) 1/24 (4%) 3.90E+00 4 17/24 (71%) 1/24 (4%) 5.58E+00
Gluconeogenesis I 15 2/17 (12%) 10/17 (59%) 3.88E+00 104 6/17 (35%) 3/17 (18%) 9.28E−01

NA, non-applicable; LXR, liver X receptor; RXR, retinoid X receptor; these pathways were not detected as regulated by CL316,243 in ERRαγAd−/− BAT. See also Figures 4, S4 and Tables S1 and S2.